FilizSenMD

Pathology • New York, NY

Hematopathology, Anatomic Pathology, Clinical Pathology

Associate Professor, Pathology and Laboratory Medicine, Hofstra North Shore-LIJ

Join to view full profile

Dr. Sen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sen's full profile

Already have an account?

Office
1275 York Avenue
New York, NY 10065

Education & Training

Duke University HospitalResidency, Pathology-Anatomic and Clinical, 1998 - 2002
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pathology-Anatomic and Clinical, 1995 - 1998
Marmara Univ- Fac MedClass of 1990

Certifications & Licensure

TX State Medical License 2002 - Present
NJ State Medical License 2021 - 2025
NY State Medical License 2010 - 2025
NC State Medical License 2004 - 2006
American Board of Pathology Anatomic Pathology & Clinical Pathology
American Board of Pathology Hematology

Publications & Presentations

PubMed

Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype.
Kimon V Argyropoulos, Umut Aypar, Mark D Ewalt, Mikhail Roshal, Ahmet Dogan
Leukemia & Lymphoma. 2023-03-01
Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features.
Victor Zibara, Filiz Sen, Michael Scordo, Lorenzo Falchi
Leukemia & Lymphoma. 2022-12-01
112 citations
GPRC5D-Targeted CAR T Cells for Myeloma.
Sham Mailankody, Sean M Devlin, Jonathan Landa, Karthik Nath, Claudia Diamonte
The New England Journal of Medicine. 2022-09-29

Abstracts/Posters

Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis
Filiz Sen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
Filiz Sen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018